Form 8-K - Current report:
SEC Accession No. 0001493152-24-049999
Filing Date
2024-12-13
Accepted
2024-12-13 16:15:31
Documents
27
Period of Report
2024-12-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 54355
2 ex1-1.htm EX-1.1 720736
3 ex4-1.htm EX-4.1 126621
4 ex4-2.htm EX-4.2 154678
5 ex5-1.htm EX-5.1 19767
6 ex5-2.htm EX-5.2 15531
7 ex99-1.htm EX-99.1 14774
8 ex99-2.htm EX-99.2 17203
9 ex99-3.htm EX-99.3 15786
10 ex5-1_001.jpg GRAPHIC 9640
11 ex5-1_002.jpg GRAPHIC 11793
12 ex5-1_003.jpg GRAPHIC 5613
13 ex5-2_001.jpg GRAPHIC 7527
14 ex5-2_002.jpg GRAPHIC 4734
  Complete submission text file 0001493152-24-049999.txt   1648718

Data Files

Seq Description Document Type Size
15 XBRL SCHEMA FILE bctx-20241211.xsd EX-101.SCH 3750
16 XBRL DEFINITION FILE bctx-20241211_def.xml EX-101.DEF 29998
17 XBRL LABEL FILE bctx-20241211_lab.xml EX-101.LAB 36631
18 XBRL PRESENTATION FILE bctx-20241211_pre.xml EX-101.PRE 27021
30 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5668
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241548558
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)